Meeting
2019 ASCO Annual Meeting
A multicenter phase II trial of rucaparib in combination with nivolumab as maintenance therapy for patients with advanced biliary tract cancer.
Authors
Vaibhav Sahai
University of Michigan, Ann Arbor, MI
Vaibhav Sahai , Nguyen H. Tran , Kent A. Griffith , Mark Zalupski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT03639935
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS4153)
DOI
10.1200/JCO.2019.37.15_suppl.TPS4153
Abstract #
TPS4153
Poster Bd #
252a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy following first-line platinum-based chemotherapy in patients with advanced biliary tract cancer (BTC): BilT-02.
First Author: Vaibhav Sahai
Poster
2022 ASCO Gastrointestinal Cancers Symposium
CA209-8YD: A phase I/II trial of rucaparib in combination with ramucirumab with or without nivolumab in previously treated advanced gastroesophageal adenocarcinoma (GEA) (RiME).
First Author: Anwaar Saeed
Poster
2023 ASCO Annual Meeting
Phase II trial of XmAb20717 (vudalimab) in patients with advanced biliary tract cancers.
First Author: William Joseph Chapin
Poster
2021 ASCO Annual Meeting
DNA-damage response-umbrella study of the combination of ceralasertib and olaparib, or ceralasertib and durvalumab in advanced biliary tract cancer: A phase 2 trial-in-progress.
First Author: Jee Sun Yoon